Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;8(7):1725-38.
doi: 10.1158/1535-7163.MCT-08-1200. Epub 2009 Jul 7.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I Raynaud  1 , Suzanne A Eccles, Sonal Patel, Sonia Alix, Gary Box, Irina Chuckowree, Adrian Folkes, Sharon Gowan, Alexis De Haven Brandon, Francesca Di Stefano, Angela Hayes, Alan T Henley, Letitia Lensun, Giles Pergl-Wilson, Anthony Robson, Nahid Saghir, Alexander Zhyvoloup, Edward McDonald, Peter Sheldrake, Stephen Shuttleworth, Melanie Valenti, Nan Chi Wan, Paul A Clarke, Paul Workman
Affiliations

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I Raynaud et al. Mol Cancer Ther. 2009 Jul.

Abstract

The phosphatidylinositide 3-kinase pathway is frequently deregulated in human cancers and inhibitors offer considerable therapeutic potential. We previously described the promising tricyclic pyridofuropyrimidine lead and chemical tool compound PI-103. We now report the properties of the pharmaceutically optimized bicyclic thienopyrimidine derivatives PI-540 and PI-620 and the resulting clinical development candidate GDC-0941. All four compounds inhibited phosphatidylinositide 3-kinase p110alpha with IC(50) < or = 10 nmol/L. Despite some differences in isoform selectivity, these agents exhibited similar in vitro antiproliferative properties to PI-103 in a panel of human cancer cell lines, with submicromolar potency in PTEN-negative U87MG human glioblastoma cells and comparable phosphatidylinositide 3-kinase pathway modulation. PI-540 and PI-620 exhibited improvements in solubility and metabolism with high tissue distribution in mice. Both compounds gave improved antitumor efficacy over PI-103, following i.p. dosing in U87MG glioblastoma tumor xenografts in athymic mice, with treated/control values of 34% (66% inhibition) and 27% (73% inhibition) for PI-540 (50 mg/kg b.i.d.) and PI-620 (25 mg/kg b.i.d.), respectively. GDC-0941 showed comparable in vitro antitumor activity to PI-103, PI-540, and PI-620 and exhibited 78% oral bioavailability in mice, with tumor exposure above 50% antiproliferative concentrations for >8 hours following 150 mg/kg p.o. and sustained phosphatidylinositide 3-kinase pathway inhibition. These properties led to excellent dose-dependent oral antitumor activity, with daily p.o. dosing at 150 mg/kg achieving 98% and 80% growth inhibition of U87MG glioblastoma and IGROV-1 ovarian cancer xenografts, respectively. Together, these data support the development of GDC-0941 as a potent, orally bioavailable inhibitor of phosphatidylinositide 3-kinase. GDC-0941 has recently entered phase I clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of phosphatidylinositide 3-kinase inhibitors and their molecular and cellular effects on cancer cells in vitro. A, chemical structures of PI-103, PI-540, PI-620, and GDC-0941. B, in vitro IC50 values for PI-103, PI-540, PI-620, and GDC-0941 against recombinant phosphatidylinositide 3-kinase enzymes. C, effects of agents on tumor cell and human umbilical vein endothelial cell (HUVEC) proliferation. Data shown as the mean of three independent determinations of GI50 following 96-h continuous exposure to compound. The tumor cell lines used exhibit a variety of mechanisms of deregulation of the phosphatidylinositide 3-kinase pathway: PC3 and U87MG are PTEN null; IGROV-1 has a hetT319F deletion and frameshift in PTEN, a p85 binding domain hetR38C mutation of p110α, and an additional hetX1069W mutation that extends the C-terminus of p110α by four amino acids; and Detroit 562 and SKOV-3 have a hetH1047R mutation of the p110α kinase domain. D, schematic of some key proteins in the phosphatidylinositide 3-kinase pathway. E, effects of agents on molecular biomarkers. Electrochemiluminescent immunoassay (Meso Scale Discovery) analysis of the phosphorylation of AKT Thr308, AKT Ser473, GSK3β Ser9, p70S6K Thr421/Ser424, and S6 ribosomal protein Ser235/Ser236. U87MG cells were treated for 2 or 8 h with 5 to 500 nmol/L phosphatidylinositide 3-kinase inhibitor or 10 to 2,500 nmol/L rapamycin. Values shown are the mean IC50 ±SD.
Figure 2
Figure 2
Pharmacokinetics of PI-540 and PI-620 in mice. A, plasma and spleen concentration-time profile of PI-540 following 10 mg/kg administration i.v. and p.o. to female BALB/c mice. Pharmacokinetic parameters are derived from WinNonlin noncompartmental analysis model 201 and 200 for i.v. and p.o., respectively. Concentrations were measured by liquid chromatography tandem mass spectrometry in A to D. B, plasma and spleen concentration versus time profile of PI-620 following 10 mg/kg administration i.v. and p.o. to female BALB/c mice. Pharmacokinetic parameters are derived from WinNonlin noncompartmental analysis model 201 and 200 for i.v. and p.o., respectively. C, plasma concentration versus time profiles following i. p. administration of PI-540 at 25, 50, and 100 mg/kg to female BALB/c mice. Pharmacokinetic parameters are derived from WinNonlin noncompartmental analysis model 200. D, plasma concentration versus time profiles following i.p. administration of PI-620 at 12.5, 25, and 50 mg/kg to female BALB/c mice. Pharmacokinetic parameters are derived from WinNonlin noncompartmental analysis model 200. Values are mean of n = 3 animals per time point.
Figure 3
Figure 3
In vivo pharmacokinetic and pharmacodynamic properties of PI-540 and PI-620 in mice. A and B, concentrations of PI-540 (A) or PI-620 (B)in plasma and tumors of NCr athymic mice bearing well-established U87MG human glioblastoma xenografts. Animals were given a single i.p. administration of compound. Plasma and tumors were collected at 0.25, 2, and 4 h following compound administration. Concentrations were measured by liquid chromatography tandem mass spectrometry. C and D, U87MG human glioblastoma xenografts were grown s.c. bilaterally in female NCr athymic mice. Animals with well established tumors were given 4 d of treatment with PI-540 at 50 mg/kg b.i.d or 100 mg/kg u.i.d i.p. At 1, 4, 6, and 8 h after the last dose, tumors were excised, snap frozen, and assayed for levels of total and Thr308 phosphorylated AKT (C) and total and Ser473 phosphorylated AKT (D). Results were obtained by electrochemiluminescent immunoassay (Meso Scale Discovery). For pharmacokinetic data, results are mean of n = 3 animals per time point. For pharmacodynamic biomaker data, results are mean ± SE of n =6.
Figure 4
Figure 4
In vivo pharmacodynamic effects of PI-540 and PI-620 in mice. U87MG human glioblastoma xenografts were grown s.c. bilaterally in female NCr athymic mice. Animals with well-established tumors were given 4 d of treatment with PI-540 at 50 mg/kg b.i.d i.p. or 100 mg/kg u.i.d i.p. (A and B) and PI-620 at 25 mg/kg b.i.d i.p. or 50 mg/kg u.i.d i.p. (C and D). At 1, 4, 6, and 8 h after the last dose, tumors were excised, snap frozen, and assayed for levels of total and Ser9 phosphorylated GSK3β (A), total and Thr421/Ser424 phosphorylated P70S6K(B), total and Thr308 phosphorylated AKT (C), and total and Ser473 phosphorylated AKT (D). Results were obtained by electrochemiluminescent immunoassay (Meso Scale Discovery). Results are mean ± SE of n =6.
Figure 5
Figure 5
In vivo pharmacodynamic properties of PI-620 and antitumor activity of PI-540 and PI-620 in mice. A and B, U87MG human glioblastoma xenografts were grown s.c. bilaterally in female NCr athymic mice. Animals with well established tumors were given 4 d of treatment with PI-620 at 25 mg/kg b.i.d i.p. or 50 mg/kg u.i.d i.p. At 1, 4, 6, and 8 h after the last dose, tumors were excised, snap frozen, and assayed for levels of total and Ser9 phosphorylated GSK3β (A) or total and Thr421/Ser424 phosphorylated P70S6K(B). Results were obtained by electrochemiluminescent immunoassay (Meso Scale Discovery). C, relative mean tumor volume (percentage of initial volume before therapy) following daily administration of PI-540 (50 mg/kg b.i.d i.p.) and PI-620 (50 mg/kg u.i.d i.p and 25 mg/kg b.i.d i.p.) for 14 d. Established tumors were grown s.c. bilaterally in female NCr athymic mice, and controls received equivalent volumes of vehicle. D, mean final tumor weights following administration of PI-540 (50 mg/kg b.i.d i.p.) and PI-620 (50 mg/kg u.i.d i.p. and 25 mg/kg b.i.d i.p.) for 14 d. For pharmacodynamic biomarker data, results are mean ± SE of n = 6. For therapy data, the results are mean ± SE of n = 16.
Figure 6
Figure 6
In vivo pharmacokinetic properties and pharmacodynamic effects of GDC-0941 in mice. A, mean plasma and tumor concentration versus time profile of GDC-0941 following a single oral administration of 50 mg/kg to female NCr athymic mice bearing s.c. U87MG human glioblastoma xenografts. B-E, U87MG human glioblastoma xenografts were grown s.c. bilaterally in female NCr athymic mice. Animals with well established tumors were given 4 d of oral treatment with GDC-0941 at 50 mg/kg or 150 mg/kg u.i.d. p.o. At 1, 4, 6, and 8 h after the last dose, tumors were excised, snap frozen, and assayed for total and Thr308 phosphorylated AKT (B), total and Ser473 phosphorylated AKT (C), total and Ser9 phosphorylated GSK3β (D), and total and Thr421/Ser424 phosphorylated P70S6K(E). Results were obtained by electrochemiluminescent immunoassay (Meso Scale Discovery). For pharmacokinetic data, results are mean ± SD of n = 3. For pharmacodynamic biomarker data, results are mean ± SE of n =6.
Figure 7
Figure 7
In vivo oral antitumor activity and associated pharmacokinetic and pharmacodynamic properties of GDC-0941 in U87MG human glioblastoma xenografts. A, relative mean tumor volume (percentage of initial volume before therapy) following 25, 50, 100, and 150 mg/kg daily doses of GDC-0941 p.o. for 19 d in the established human U87MG human glioblastoma xenograft model. Tumors were grown s.c. bilaterally in female NCr athymic mice, and controls received equivalent volumes of vehicle. B, mean final tumor weights for the U87MG human glioblastoma xenograft model following 25, 50, 100, and 150 mg/kg daily GDC-0941 p.o. for 19 d. C, pharmacodynamic effects in the U87MG human glioblastoma xenograft model. Tumors were from the same efficacy study as shown in A and B and were taken 4 and 8 h following the final dose. AKT phosphorylation Ser473 and total AKT were measured by electrochemiluminescent immunoassay (Meso Scale Discovery). D, tumor concentrations of GDC-0941 in the U87MG human glioblastoma xenograft model measured by liquid chromatography tandem mass spectrometry following 19 d daily oral dosing with 25, 50, 100, and 150 mg/kg in the efficacy study. Tumors were collected 4 and 8 h after the final dose. For therapy data, results are mean ± SE of n = 16. For pharmacodynamic biomarker data, results are mean ± SE of n = 6. For pharmacokinetic data, results are mean ± SD of n = 3.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997;22:267–72. - PubMed
    1. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem. 1999;274:8347–50. - PubMed
    1. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7. - PubMed
    1. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta. 1998;1436:127–50. - PubMed
    1. Crabbe T, Welham MJ, Ward SG. The PI3K inhibitor arsenal: choose your weapon! Trends Biochem Sci. 2007;32:450–6. - PubMed

Publication types

MeSH terms

-